Nootropic Peptides: Peptide Class Overview

Nootropic peptides are short synthetic or endogenous sequences that exert their primary effects on the central nervous system, targeting cognition, anxiety regulation, sleep architecture, or neuroprotection. The class is defined by its clinical target: modulating brain function through peptidergic signaling pathways rather than through classical small-molecule receptor agonism or antagonism.

Three compounds anchor the current research landscape in this category: Semax, Selank, and DSIP. All three emerged from Soviet and post-Soviet neuroscience programs, share intranasal or parenteral routes as primary delivery paths, and act on distinct but partially overlapping neuromodulatory systems. Two (Semax and Selank) have received regulatory approval in Russia. DSIP remains a pure research compound globally.

This page is a high-level orientation to the class. Detailed mechanistic, pharmacokinetic, and evidence profiles are on each compound’s hub page.

What Nootropic Peptides Share

The three compounds in this class converge on two overarching biological outcomes despite different upstream mechanisms:

1. Enhancement of neurotrophic factor expression. Semax and Selank both upregulate BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in hippocampal and prefrontal circuits, supporting neuroplasticity and synaptic consolidation. DSIP indirectly supports neurotrophic biology through antioxidant enzyme upregulation and CREB phosphorylation in contexts of hypoxic stress (PMID: 30107169).

2. Modulation of stress and arousal circuits. Each compound acts on the hypothalamus, limbic system, or thalamic circuits to shift the balance between stress-mobilization signals (ACTH, CRH, cortisol) and inhibitory or restorative signals (GABA tone, NREM sleep, somatostatin). The net effect across the class is attenuation of excessive arousal while preserving or improving cognitive throughput.

None of the three compounds holds an FDA-approved drug indication. Semax and Selank carry Russian Ministry of Health approval for specific indications (ischemic stroke/cognitive disorders and generalized anxiety disorder, respectively). All research outside Russia is classified as investigational. No dosing guidance or clinical recommendations are presented on this page.

Brief History of the Class

1974. Marcel Monnier and colleagues at the University of Basel isolated a nine-amino-acid peptide from the cerebral venous blood of sleep-deprived rabbits. Infusion of the dialysate into waking recipient rabbits produced EEG slow-wave patterns and behavioral sleep. The sequence was named delta sleep-inducing peptide (DSIP) and published in Pflugers Archiv (PMID: 4606802). DSIP became the first functionally defined neuropeptide of this class.

1980s. Nikolai Myasoedov and colleagues at the Institute of Molecular Genetics of the Russian Academy of Sciences developed Semax by taking the ACTH(4-10) heptapeptide fragment, which was already known to have cognitive effects without adrenocortical activity, and appending a Pro-Gly-Pro C-terminal sequence to enhance CNS stability. Preclinical studies demonstrated BDNF and NGF upregulation in hippocampal tissue.

1984. Schneider-Helmert and Schoenenberger published the first human DSIP sleep trial, a double-blind crossover study in chronic insomnia patients. The study found reduced sleep latency and improved sleep efficiency, but sample sizes were small and subsequent replication was inconsistent. The inconsistency established DSIP as a sleep modulator rather than a direct sleep inducer, a framing that persists today.

1990s. The same Institute of Molecular Genetics team developed Selank by modifying tuftsin, a naturally occurring tetrapeptide immunomodulator (Thr-Lys-Pro-Arg), with the same Pro-Gly-Pro stabilizing extension used in Semax. Early preclinical studies revealed unexpectedly potent anxiolytic activity. GABAergic and serotonergic mechanisms were characterized in rodent anxiety models.

1994. Semax received regulatory approval in Russia for clinical use in ischemic stroke and cognitive disorders. It became one of the first neuropeptides to enter approved clinical practice in any jurisdiction.

2000s. Mechanistic studies clarified Semax’s downstream signaling: MC3R/MC4R (melanocortin receptor) binding triggers CREB phosphorylation, which drives BDNF, NGF, and TrkB receptor upregulation. The prolonged neurotropic effects lasting 20-24 hours after peptide clearance were attributed to this gene-expression cascade rather than direct receptor occupancy.

2005-2009. Selank’s Phase II and III clinical trials in Russia demonstrated efficacy comparable to low-dose benzodiazepines for generalized anxiety disorder without sedation, cognitive impairment, or withdrawal. Selank received Russian Ministry of Health approval in 2009 as an intranasal anxiolytic.

2010-2018. DSIP research shifted from sleep pharmacology toward neuroprotection and antioxidant biology. Studies in aged rats showed upregulation of SOD, catalase, and glutathione peroxidase (PMID: 25257425). Hepatoprotective effects under restraint stress were characterized (PMID: 26902351). The phosphorylated analog (pDSIP) was shown to restore spatial memory and CREB phosphorylation at high altitude by improving sleep architecture in a hypoxic rat model (PMID: 30107169).

2021-present. DSIP and a structural analog (KND peptide, Lys-Asn-Asp) reduced infarct volume in focal stroke (PMID: 34500605) and myocardial ischemia-reperfusion models (PMID: 33918965), extending its research profile beyond sleep into acute cytoprotection. Semax and Selank research has expanded into ADHD, anxiety-cognition combination protocols, and gene expression analyses.

Shared Pathway: Convergent Neuromodulatory Mechanisms

The three compounds act through distinct upstream targets but converge on overlapping outputs in stress regulation, neuroprotection, and neurotrophic support. The diagram maps these relationships.

flowchart TD
    SEMAX["Semax\n(ACTH 4-10 + Pro-Gly-Pro)"]
    SELANK["Selank\n(Tuftsin analog + Pro-Gly-Pro)"]
    DSIP["DSIP\n(Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)"]

    SEMAX --> MCR["MC3R / MC4R binding\n(melanocortin receptors)"]
    MCR --> CREB_S["CREB phosphorylation\n(Semax-driven)"]
    CREB_S --> NTF["BDNF + NGF upregulation\nTrkB receptor expression"]

    SELANK --> GABA["GABA-A receptor\nallosteric modulation"]
    SELANK --> SERO["5-HT metabolism\nnormalization"]
    SELANK --> CREB_SE["BDNF + NGF upregulation\n(shared with Semax)"]

    DSIP --> HYP["Hypothalamic modulation\nGHRH stim / somatostatin inhib"]
    DSIP --> CRH["CRH signaling\nattenuation under stress"]
    DSIP --> AOX["Antioxidant enzyme\nupregulation: SOD, catalase"]
    DSIP --> CREB_D["p-CREB expression\n(pDSIP, hypoxic model)"]

    NTF --> PLAST["Neuroplasticity\nsynaptogenesis, LTP"]
    CREB_SE --> PLAST
    CREB_D --> PLAST

    GABA --> ANX["Anxiety attenuation\nCalm alertness"]
    SERO --> ANX
    CRH --> ANX

    AOX --> NEUROPROT["Neuroprotection\ninfarct volume reduction"]
    HYP --> SLEEP["NREM sleep promotion\n(DSIP primary effect)"]

    PLAST --> COG["Cognitive output:\nAttention, memory, processing speed"]
    ANX --> COG
    SLEEP --> COG
    NEUROPROT --> COG

Compound Comparison Table

Key Differentiators Within the Class

Receptor definition. Semax and Selank both have characterized receptor interactions that ground their mechanistic interpretation. Semax acts on melanocortin receptors (MC3R and MC4R), which are established GPCRs with cloned sequences, crystal structures, and pharmacological toolkits. Selank’s primary target is the GABA-A receptor complex via allosteric modulation, distinct from the benzodiazepine binding site. DSIP, by contrast, has no confirmed cloned receptor after more than 50 years of research. This “orphan peptide” status limits selectivity assessment, structure-activity work, and mechanistic certainty for DSIP in ways that do not apply to Semax or Selank.

Primary clinical target. The three compounds were developed against distinct primary endpoints. Semax targets cognitive enhancement and neuroprotection in ischemic or degenerative contexts. Selank targets anxiety without sedation; its design goal was a benzodiazepine replacement with preserved cognition. DSIP was identified through its sleep-promoting activity and remains primarily a sleep-biology and stress-modulation research compound, with secondary interest in neuroprotection and antioxidant aging research.

Human evidence depth. Semax and Selank have the strongest human evidence in the class, supported by Russian regulatory approval and clinical datasets spanning over a decade of post-marketing use. DSIP’s human evidence base is thin: the 1984 Schneider-Helmert insomnia study represents the primary human data, and replication has not been consistent. No registered Phase II or Phase III trial for DSIP appears on ClinicalTrials.gov as of April 2026.

Route and BBB access. Semax and Selank are both administered intranasally, exploiting olfactory pathway access to bypass the blood-brain barrier and avoid first-pass hepatic metabolism. Plasma half-life is short (30-60 minutes for Semax; 30-45 minutes for Selank), but neurotropic effects persist for hours to days via transcriptional mechanisms downstream of receptor engagement. DSIP has documented blood-brain barrier penetration in animal models, enhanced by phosphorylation of its Ser7 residue (PMID: 25805003). Research into engineered DSIP constructs fused with protein transduction domains has sought to improve CNS delivery systematically (PMID: 28462721).

Anxiety vs. cognition balance. Semax and Selank are often combined in Russian clinical and research protocols because their primary mechanisms are orthogonal: Semax drives neurotrophic factor upregulation for cognitive enhancement, while Selank provides GABAergic anxiolysis. Together they address both the cognitive and anxiety-load dimensions of performance under stress, a combination that has been studied in gene expression analyses examining hippocampal tissue. DSIP does not fit neatly into either category; its effects on anxiety are secondary to its neuroendocrine modulation of CRH and cortisol pathways rather than direct GABAergic action.

Immunomodulatory activity. Selank uniquely retains the immunomodulatory activity of its tuftsin backbone. Tuftsin stimulates phagocyte function and modulates IL-6 and T-cell balance; Selank preserves this activity alongside its anxiolytic properties. Semax and DSIP do not have defined immunomodulatory mechanisms at the same depth.

Research Outlook and Open Questions

DSIP receptor identification. The most fundamental open question in this class is the molecular identity of the DSIP receptor, assuming one exists. Until a receptor is cloned and confirmed, selectivity cannot be characterized, structure-activity relationships remain purely empirical, and on-target versus off-target mechanisms for all observed DSIP effects remain ambiguous. This limits the compound’s development trajectory compared to receptor-defined peptides like Semax and Selank.

Human PK outside Russia. For Semax and Selank, the intranasal pharmacokinetics reported in Russian clinical literature have not been independently characterized in Western populations with modern bioanalytical methods. Plasma half-life values (approximately 30-60 minutes for Semax; 30-45 minutes for Selank) derive from Russian PK studies. Quantitative CNS exposure data from human CSF sampling are not in the public literature.

Sustained neurotrophic effects. Semax’s claimed neurotropic effects lasting 20-24 hours following a dose with a 30-60 minute plasma half-life represent an important mechanistic claim. The proposed explanation is CREB-driven transcriptional upregulation of BDNF and NGF that outlasts the peptide. Direct measurement of BDNF protein levels in human CSF or brain tissue following a defined Semax dose has not been published in peer-reviewed form outside Russian sources.

Phospho-DSIP. The phosphorylated form of DSIP (pDSIP) shows greater CNS activity than native DSIP in preclinical models, attributed to enhanced BBB penetration (PMID: 30107169). Whether pDSIP represents a meaningfully distinct pharmacological entity for human development, or whether phosphorylation is simply a PK modifier, has not been resolved in any clinical study.

Combination pharmacology. The Semax + Selank combination is widely used in Russian clinical practice and in international research settings, on the basis that their mechanisms are non-overlapping. Formal PK interaction studies, controlled efficacy comparisons against each agent alone, and safety data for prolonged combination use have not been published in peer-reviewed international journals.

ADHD and attention applications. Russian clinical data and recent research suggest Semax may improve sustained attention and working memory in profiles consistent with ADHD-like presentations, without stimulant mechanisms. No controlled trial data from outside Russia exist, and the compound has not entered any Western regulatory pathway for this indication.

DSIP neuroprotection mechanism. Preclinical data showing DSIP and its KND analog reduce infarct volume in stroke and reperfusion models (PMID: 34500605; PMID: 33918965) raise the question of whether the cytoprotective mechanism is dependent on sleep-induction, antioxidant enzyme upregulation, HPA axis modulation, or a combination. Resolving this is a prerequisite for developing DSIP analogs as neuroprotective agents.

Long-term safety outside Russia. For Semax, 25+ years of Russian clinical post-marketing data provide a qualitative safety record; reported adverse effects are minimal (nasal irritation in 10-15% of users; rare transient headache). For Selank, 15+ years of Russian clinical use support a similar profile. Neither compound has undergone a formal Phase III placebo-controlled safety trial outside Russia with prospective adverse event monitoring over multi-year follow-up.

Compound Hubs

Detailed evidence, mechanism, pharmacokinetics, safety, and dose-response data are organized by compound:

• Semax Research Hub
• Selank Research Hub
• DSIP Research Hub

This page is for research and educational purposes. It does not constitute medical advice, dosing guidance, or a recommendation to use any compound. Consult a licensed clinician for individualized guidance.

See also

Compounds in this family:

• Semax
• Selank
• Dsip